Clinical trial

Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

NCT04221529

Study summary

ClinicalTrials.gov

Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Atezolizumab Normalized identity: atezolizumab View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-01-06

PhasePHASE2

Conditions

SCLC, Extensive Stageunresolved

Interventions

AtezolizumabDRUG · verified · RxNorm: atezolizumab

Sponsors & collaborators

AIO-Studien-gGmbHlead sponsor

Hoffmann-La Rochecollaborator

Mapped research locations

HamburgGermany1 ViennaAustria1 MünchenGermany1 HeidelbergGermany1 Freiburg im BreisgauGermany1 BochumGermany1 HalleGermany1 GroßhansdorfGermany1 MarburgGermany1 WiesbadenGermany1 WuppertalGermany1 Esslingen am NeckarGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04221529 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.